Breaking Finance News

Zacks Investment Research downgraded Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) to Hold in a report released today.

Zacks Investment Research has downgraded Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) to Hold in a report released on 05/23/2017.

Just yesterday Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) traded 5.12% higher at $7.17. Akari Therapeutics PLC (ADR)’s 50-day moving average is $5.83 and its 200-day moving average is $6.72. The last stock price is up -35.82% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.01% over the same time period. 520,942 shares of AKTX traded hands, up from an average trading volume of 427,051

Recent Performance Chart

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

Akari Therapeutics PLC (ADR) has 52 week low of $3.18 and a 52 week high of $22.20 and has a market capitalization of $0.

Brief Synopsis On Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *